NIH is studying the shingles vaccine and dementia connection because several large studies suggest that vaccination may be associated with fewer dementia diagnoses, but researchers still do not know whether the vaccine itself causes that reduction. For example, an NIH-funded study in Wales found that receiving a shingles vaccine reduced the probability of a dementia diagnosis by about 20% over seven years. The finding is promising enough to investigate, but it is not proof that shingles vaccination prevents dementia. To evaluate the evidence, the National Institute on Aging, the National Institute of Allergy and Infectious Diseases, and the National Institute of Neurological Disorders and Stroke jointly organized a June 1–2, 2026 workshop titled “Zoster Vaccine and Dementia Risk Reduction: Evidence and Mechanisms.” The meeting focused on epidemiology, possible biological mechanisms, useful datasets, and the design of clinical trials.
NIH is supporting analyses and scientific coordination, but it is not the sponsor of the two current randomized Shingrix trials in Finland and Denmark. That distinction matters for patients and families. Shingrix is used to prevent shingles and its complications; it is not approved by the Food and Drug Administration or recommended by the Centers for Disease Control and Prevention as a way to prevent dementia. The research may eventually clarify whether vaccination has an additional neurological benefit, but current dementia care decisions should not treat that possibility as established medicine.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why Is NIH Studying the Shingles Vaccine and Dementia Connection?
- What the Welsh Natural Experiment Actually Found
- What Shingrix Studies Add to the Evidence
- How Patients and Families Should Use This Information
- Bias, Diagnosis, and the Limits of Observational Research
- How a Shingles Vaccine Might Affect the Brain
- The Randomized Shingrix Trials Underway in Finland and Denmark
- Frequently Asked Questions
Why Is NIH Studying the Shingles Vaccine and Dementia Connection?
Scientists are interested because the association has appeared in different populations, healthcare systems, and study designs. NIH’s 2026 workshop announcement highlighted the Welsh result as well as newer research involving Shingrix, the recombinant vaccine now routinely used in the United States. When several datasets point in a similar direction, researchers have reason to ask whether they are seeing a genuine biological effect or the same hidden bias repeated in different forms. The Welsh research offered an unusually informative example. Wales introduced a shingles vaccination program in 2013 with a strict birth-date eligibility cutoff.
People born just before the cutoff could receive the vaccine, while those born shortly afterward generally could not. Researchers compared adults on either side of that boundary, creating what is known as a natural experiment. Unlike a typical medical-record comparison between people who voluntarily get vaccinated and those who do not, eligibility depended largely on a date rather than an individual health decision. NIH’s role is to help determine what evidence would be strong enough to change scientific understanding or clinical practice. A workshop can compare datasets, identify plausible mechanisms, and improve trial design, but it cannot establish that a vaccine prevents dementia. That requires careful replication and, preferably, randomized evidence with dementia specified as an outcome.
What the Welsh Natural Experiment Actually Found
The Nature study, published April 2, 2025, analyzed 282,541 Welsh adults who had no previous dementia diagnosis. Over a primary follow-up period of seven years, eligibility for shingles vaccination was associated with roughly a one-fifth reduction in new dementia diagnoses. NIA described the result as a 20% reduction in the probability of receiving a dementia diagnosis. The study was quasi-experimental, not a randomized clinical trial. Its birth-date cutoff made the vaccinated and comparison groups more similar than the groups in many conventional observational studies, strengthening the argument that vaccination could have played a role. Even so, natural experiments depend on assumptions.
Researchers must consider whether the eligibility cutoff affected healthcare access or behavior in other ways and whether administrative diagnoses captured dementia consistently. There is another important limitation: the finding involved Zostavax, an older live-attenuated shingles vaccine. It did not directly test Shingrix, the recombinant vaccine used as the current U.S. standard. The authors noted that Shingrix replaced Zostavax in the United Kingdom only after the study’s follow-up ended, and they cautioned that confirmation in other populations is critical. A protective effect associated with one vaccine platform cannot automatically be assigned to another.
What Shingrix Studies Add to the Evidence
A U.S. retrospective study published in Nature Medicine in October 2024 compared matched groups of people who received Shingrix or Zostavax. Two Shingrix doses were associated with a 17% longer period without a dementia diagnosis over six years than Zostavax. The association was stronger among women, a difference that raises useful questions about immune responses and sex-related biology but does not yet provide a clinical rule for individual patients. NIH’s May 2026 summary also cited a newer U.S.
cohort study in which two doses of Shingrix were associated with a 51% lower dementia risk. The underlying Kaiser Permanente study used analyses intended to address “healthy vaccinee” bias—the possibility that vaccinated people are healthier, more engaged with medical care, or more likely to follow preventive recommendations from the outset. Neither result proves prevention. Matching people by recorded characteristics cannot account perfectly for factors that were never measured or documented. For example, a person who completes a two-dose vaccine series may also be more likely to exercise, control blood pressure, attend follow-up visits, or seek evaluation for memory symptoms. Those differences can affect dementia rates independently of the vaccine.
How Patients and Families Should Use This Information
People who already qualify for Shingrix can discuss it with a healthcare professional for its established purpose: preventing shingles and related complications, including persistent nerve pain. The possible dementia association may be scientifically encouraging, but it should not replace the approved reason for vaccination or become a promise that the vaccine will preserve memory. The tradeoff is straightforward. Shingrix has evidence and public-health recommendations supporting shingles prevention, while dementia prevention remains under study.
A patient deciding whether to be vaccinated should consider age, immune status, prior vaccination, medical history, and expected vaccine reactions under current clinical guidance—not assume that a dose provides neurological protection. Families should also avoid substituting shingles vaccination for established brain-health and medical care. Managing high blood pressure, addressing hearing loss, reviewing medications, staying physically active when possible, and obtaining an evaluation for new cognitive symptoms remain separate issues. If an older adult begins missing bills or getting lost, scheduling a cognitive assessment is more appropriate than treating vaccination as a response to those symptoms.
Bias, Diagnosis, and the Limits of Observational Research
Dementia research based on health records faces a basic problem: a recorded diagnosis is not identical to the biological onset of disease. Alzheimer’s disease and other dementias can develop for years before being recognized. Differences in medical visits, screening, diagnostic coding, or survival can change how many cases appear in each study group. Healthy vaccinee bias is another persistent concern. People who seek vaccines may differ from nonrecipients in education, income, mobility, access to care, frailty, and preventive habits.
Statistical adjustments and matched cohorts reduce this imbalance, but they cannot guarantee that it has disappeared. Even a large effect estimate can be misleading if an unmeasured difference is strongly related to both vaccination and dementia risk. Researchers must also separate relative changes from individual outcomes. A 20% relative reduction in diagnoses does not mean that 20 out of every 100 vaccinated people will avoid dementia. The personal effect depends on the starting risk, age, length of follow-up, competing health risks, and whether the observed association is causal. Study percentages from Wales, Kaiser Permanente, and other cohorts should not be compared as though they came from one uniform experiment.
How a Shingles Vaccine Might Affect the Brain
Several mechanisms could explain a genuine connection. Preventing reactivation of varicella-zoster virus might reduce episodes of inflammation, vascular injury, or immune activity that could contribute to cognitive decline. Vaccination might also alter broader immune responses in ways relevant to the aging brain.
NIH’s workshop was organized partly to examine these possibilities rather than assuming that the epidemiological association explains itself. A real-world example illustrates the uncertainty: shingles can cause substantial inflammation and neurological complications, so preventing infection could plausibly protect health beyond avoiding a painful rash. Yet biological plausibility is not clinical proof. Researchers still need to determine whether reduced viral reactivation, vaccine-stimulated immunity, or an unrelated characteristic of vaccinated populations best accounts for the dementia findings.
The Randomized Shingrix Trials Underway in Finland and Denmark
A large GSK-sponsored Phase IV study in Finland, NCT07502560, is recruiting adults aged 76 and older. It plans to enroll 33,609 participants and randomly assign them in a 3:1 ratio to recombinant zoster vaccine or placebo. The estimated primary completion date is April 1, 2030, and study completion is estimated for March 31, 2037. No dementia-prevention results have been posted, and the trial is not an FDA approval decision.
A separate investigator-sponsored trial in Denmark, DAN-ZOSTER, NCT07485283, began April 28, 2026. It plans to randomize approximately 162,000 adults aged 65 and older to receive two Shingrix doses or no study vaccination, with incident dementia as one of two dual-primary outcomes. The record explicitly notes that randomized evidence for dementia prevention is lacking and estimates primary completion in April 2029. Its sponsor is Tor Biering-Sørensen of Herlev and Gentofte Hospital, not NIH.
Frequently Asked Questions
Does Shingrix prevent dementia?
That has not been established. Observational studies have found associations between Shingrix and lower dementia risk, but Shingrix is not FDA-approved or CDC-recommended for dementia prevention.
Did NIH run the Welsh shingles vaccine study?
The Welsh analysis received NIH funding, and NIA has highlighted its findings. It was a natural experiment based on Wales’s vaccination eligibility rules, not an NIH-run randomized trial.
Was the Welsh study about Shingrix?
No. It examined Zostavax, the older live-attenuated vaccine. Shingrix did not replace Zostavax in the United Kingdom until after the study’s follow-up period.
Why are randomized trials necessary?
Random assignment helps balance health behaviors and other characteristics that can distort observational results. It offers a stronger test of whether vaccination itself changes dementia incidence.
Is NIH sponsoring the randomized trials in Finland and Denmark?
No. GSK sponsors the Finnish trial. The Danish trial is sponsored by Tor Biering-Sørensen of Herlev and Gentofte Hospital.
Should someone get Shingrix solely to lower dementia risk?
Current evidence does not support presenting Shingrix as a dementia-prevention treatment. Vaccination decisions should be based on its established use against shingles and discussed with a qualified healthcare professional.
